Skip to main content

Table 2 Central macular thickness changes compared with baseline during follow-up

From: Combined intravitreal injection of bevacizumab and a ROCK inhibitor (fasudil) for refractory macular edema secondary to retinal vein occlusion: a pilot study

  

Mean ± SD

Median (range)

Baseline (µm)

CMT

607 ± 271

643 (257–1166)

Month 3

CMT

404 ± 185

315 (234,882)

 

Change

−206 ± 299

−93 (−856–129)

 

P-value within

0.028

 

Month 6

CMT

412 ± 146

361 (188,698)

 

Change

−183 ± 226

−148 (−637,228)

 

P-value within

0.007

 

Month 9

CMT

414 ± 154

420 (233,810)

 

Change

−209 ± 249

−220 (−698,144)

 

P-value within

0.01

 

Month 12

CMT

379 ± 125

404 (200,605)

 

Change

−223 ± 227

−149 (−581,57)

 

P-value within

0.004

 
  1. CMT central macular thickness